MedTrace Logo

Evaluation of Transgenic Lymphocyte Immunization Vaccine in Subjects With Prostate Adenocarcinoma

NCT00061035 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2008-08-28

No results posted yet for this study

Summary

Dr. Frederick Millard, MD, Associate Clinical Professor at the UCSD Cancer Center, will be conducting a 12-week study in advanced prostate cancer patients. The study will be held at the UCSD Medical Center and will test an experimental investigational gene therapy vaccine designed to make the patient's immune system react against telomerase, an enzyme expressed in prostate cancer cells.

Conditions

  • Prostatic Neoplasms

Interventions

BIOLOGICAL

Transgenic Lymphocyte Immunization Vaccine (TLI)

Sponsors & Collaborators

  • Cosmo Bioscience

    lead INDUSTRY

Principal Investigators

  • Frederick E. Millard, M.D · Associate Professor of Medicine at UCSD and Medical Director of the CTO of the UCSD Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00061035 on ClinicalTrials.gov